New funding allows Azura to advance study of MGD treatment

Azura Ophthalmics has raised $20 million in financing for registration studies of its lead clinical candidate for treatment of meibomian gland dysfunction, according to a press release.
The company received the round of funding after receipt of “encouraging” phase 2 data of its AZR-MD-001 (selenium disulfide) treatment for MGD, the release said.
Existing investors OrbiMed, TPG Biotech, Brandon Capital’s Medical Research Commercialization Fund and Ganot Capital led the funding round.
AZR-MD-001 is formulated as an ointment intended to address abnormal hyperkeratinization as a

Full Story →